Breaking News, Collaborations & Alliances

Onconova, SymBio Complete License Agreement

Onconova Therapeutics and SymBio Pharmaceuticals will collaborate to develop and commercialize rigosertib in Japan and Korea.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Onconova Therapeutics and SymBio Pharmaceuticals will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting Phase III trials with rigosertib for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors. The FDA has granted orphan drug designation for the use of rigosertib in MDS, and a Special Protocol Assessment (SPA) for the Phase III trial design. SymBio has an exclusive license to develop and commercialize rigosertib in Japan and Korea. Onco...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters